Abstract
Gemcitabine and rebeccamycin are molecules which present antitumoral activity. The first one is currently used as single agent in pancreatic cancer treatment or in combination with other drugs in several types of cancer, while analogues of the second have been tested in phase II clinical trials in breast and lung cancers. Gemcitabine is an analogue of deoxycytidine that inhibits DNA synth…